Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Pharmaceuticals Stock Is Up Today

By Prosper Junior Bakiny – Aug 13, 2020 at 6:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After a rough week on the stock market for the biotech company, investors finally think the price is right.

What happened?

Shares of the biotech Inovio Pharmaceuticals (INO 3.51%) are rising sharply today, up by 5.9% as of 12:23 p.m. EDT, despite the company not reporting any news. But with the company down by nearly 29% over the past five days alone, it seems reasonable to assume that investors think now is a good time to scoop up Inovio's shares for a discount. 

So what

Inovio released its second-quarter financial report on Aug. 10. The big story from the company's earnings release was an update regarding its efforts to develop a vaccine for COVID-19. Inovio reported that in a phase 1 clinical trial, all of the participants demonstrated immune responses after receiving its experimental vaccine, INO-4800. In particular, about 90% of the study's participants generated strong T cell responses. Also, Inovio's candidate performed well in a non-human primate study as part of Operation Warp Speed.

Doctor holding a glass vial with a sign that says "COVID-19 vaccine coronavirus."

Image source: Getty Images.

INO-4800 prevented infections from the SARS-CoV-2 virus -- the virus that causes COVID-19 -- in rhesus macaques 13 weeks after the last vaccination. Inovio plans on starting a phase 2/3 clinical trial this summer. With this potential catalyst on the way, some investors believe that the company will recover from its recent poor performances on the stock market. 

Now what

Inovio's stock will continue to be volatile moving forward. The progress of its COVID-19 program will spell good news for its shareholders, but several things could send its stock tumbling, including the work of other biotechs in the COVID-19 battle. For that reason, Inovio remains a high-risk, high-reward play. Those who can stomach the risk and decide to initiate a position in the company could rack up solid gains between now and the end of the year. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.